Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab for advanced gastric and colorectal cancer (observational)
ChiCTR2100051186Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Henan University of Science and Technology
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in gastric cancer (GC) and colorectal cancer (CRC), sponsored by First Affiliated Hospital of Henan University of Science and Technology. Primary endpoint: overall survival. Started Sep 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100051186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051186.